Managed Access Programs for INC424, Ruxolitinib

Inclusion criteria

• ✓. An independent request was received from a licensed physician.
• ✓. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
• ✓. The patient is not eligible or able to enroll in a clinical trial or continue participation in such trial.
• ✓. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
• ✓. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
• ✓. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
• ✓. Managed Access provision is allowed per local laws/regulations.